{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:27:22Z","timestamp":1794472042580,"version":"4.9.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"DOI":"10.1007\/s40265-026-02393-z","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:18Z","timestamp":1792068858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rocbrutinib: First Approval"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"1","key":"2393_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","volume":"17","author":"M Shirley","year":"2022","unstructured":"Shirley M. Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features. Target Oncol. 2022;17(1):69\u201384.","journal-title":"Target Oncol"},{"key":"2393_CR2","unstructured":"Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care, China Anti-Cancer Association Lymphoma Committee, Chinese Association for Clinical Oncologists, et al. China lymphoma diagnosis and treatment guideline (2026 edition). Zhonghua Zhong Liu Za Zhi [Chin J Oncol]. 2026;48(3):263\u2013309."},{"issue":"Suppl 1","key":"2393_CR3","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1182\/blood-2024-205775","volume":"144","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, Brander DM, Hu B, et al. LP-168 (rocbrutinib), a novel covalent and non-covalent next-generation inhibitor of Bruton\u2019s tyrosine kinase: updates on the phase 1 trial and initial results of the CLL gatekeeper mutation cohort [abstract]. Blood. 2024;144(Suppl 1):4622\u20133.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2393_CR4","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2025-1532","volume":"146","author":"B Gordon","year":"2025","unstructured":"Gordon B, Cool L, Muhowski E, et al. Targeting BTKi-resistant CLL using the dual irreversible\/reversible 4th generation BTK inhibitor rocbrutinib [abstract]. Blood. 2025;146(Suppl 1):1532\u20133.","journal-title":"Blood"},{"key":"2393_CR5","unstructured":"Lupeng Pharmaceutical. Rocbrutinib: Chinese prescribing information. 2026. Accessed 11 Aug 2026."},{"key":"2393_CR6","unstructured":"National Medical Products Administration. NMPA approval notice [media release]. 4 June 2026. https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxypxx\/20260604155744140.html."},{"key":"2393_CR7","unstructured":"National Medical Products Administration. Drug approval document delivery information. 2026. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20260608163307141.html. Accessed 9 Sept 2026."},{"key":"2393_CR8","unstructured":"Lupeng Pharmaceutical. Lupeng Pharmaceutical\u2019s next-generation BTK inhibitor, rocbrutinib (LP-168 tablets), has been included in the Breakthrough Therapy List [media release]. 9 May 2024. https:\/\/www.lupengbio.com\/NewsCenter\/480.html."},{"key":"2393_CR9","unstructured":"Center for Drug Evaluation. Breakthrough therapy announcement. 2026. https:\/\/www.cde.org.cn\/main\/xxgk\/listpage\/. Accessed 9 Sept 2026."},{"key":"2393_CR10","unstructured":"Jiangsu Hansoh Pharmaceutical. Hansoh Pharma received approval from NMPA for clinical trial of Hs-10561, a small molecule BTK inhibitor for chronic spontaneous urticaria [media release]. 25 Feb 2025. https:\/\/www.hspharm.com\/news\/news-detail-513286.htm."},{"issue":"Suppl 1","key":"2393_CR11","doi-asserted-by":"publisher","first-page":"7407","DOI":"10.1182\/blood-2025-7407","volume":"146","author":"W Han","year":"2025","unstructured":"Han W, Guzman EC, Bhattacharya A, et al. Profiling drug sensitivity in CLL B cells after BTK inhibitor progression using a novel drug panel [abstract]. Blood. 2025;146(Suppl 1):7407\u20138.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2393_CR12","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1182\/blood-2024-203522","volume":"144","author":"BK Gordon","year":"2024","unstructured":"Gordon BK, Whipp EC, Yu LB, et al. Genome-wide CRISPR\/Cas9 knockout screen reveals novel LP-168 (rocbrutinib) combinations targeting BCL-2 protein members for chronic lymphocytic leukemia [abstract]. Blood. 2024;144(Suppl 1):3587\u20138.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2393_CR13","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1182\/blood-2025-886","volume":"146","author":"YQ Song","year":"2025","unstructured":"Song YQ, Cai QQ, Tang XQ, et al. Efficacy and safety of rocbrutinib, the fourth generation Bruton\u2019s tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory mantle cell lymphoma: results from a phase II ROCK-1 trial [abstract]. Blood. 2025;146(Suppl 1):886\u20137.","journal-title":"Blood"},{"key":"2393_CR14","doi-asserted-by":"publisher","unstructured":"Zhu J, Song Y, Cai Q, et al. Rocbrutinib in covalent BTK inhibitor exposed relapsed or refractory mantle cell lymphoma: a phase 2, open-label, multicenter, single-arm study [preprint] 2026. https:\/\/doi.org\/10.21203\/rs.3.rs-9538133\/v1.","DOI":"10.21203\/rs.3.rs-9538133\/v1"},{"issue":"Suppl 1","key":"2393_CR15","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1182\/blood-2025-3587","volume":"146","author":"YQ Song","year":"2025","unstructured":"Song YQ, Cai QQ, Zhou KS, et al. Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory mantle cell lymphoma (R\/R MCL): updated results from the phase 1 study [abstract no.]. Blood. 2025;146(Suppl 1):3587\u20138.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2393_CR16","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2025-3896","volume":"146","author":"YQ Song","year":"2025","unstructured":"Song YQ, Cai QQ, Zhou KS, et al. Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) [abstract]. Blood. 2025;146(Suppl 1):3896\u20137.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2393_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/blood-2025-87","volume":"146","author":"J Woyach","year":"2025","unstructured":"Woyach J, Brander D, Hu BY, et al. Updates of R\/R CLL with prior exposure to Bruton\u2019s tyrosine kinase (BTK) inhibitor and\/or BCL-2 inhibitor in the phase 1 trial of LP-168 (rocbrutinib), a novel covalent and non-covalent BTK inhibitor [abstract]. Blood. 2025;146(Suppl 1):87\u20138.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2393_CR18","first-page":"1504","volume":"10","author":"L Fu","year":"2026","unstructured":"Fu L, Zhou K, Sun X, et al. First report of rocbrutinib for the treatment of patients with relapsed or refractory primary central nervous system lymphoma [abstract no. PF1033]. HemaSphere. 2026;10(Suppl 1):1504\u20135.","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"2393_CR19","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1182\/blood-2024-194561","volume":"144","author":"YQ Song","year":"2024","unstructured":"Song YQ, Cai QQ, Zhou KS, et al. Rocbrutinib, a new-generation BTK inhibitor, demonstrates safety and efficacy in relapsed\/refractory non-GCB diffuse large B cell lymphoma [abstract]. Blood. 2024;144(Suppl 1):3119\u201320.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2393_CR20","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2024-194572","volume":"144","author":"YQ Song","year":"2024","unstructured":"Song YQ, Cai QQ, Zhou KS, et al. Safety and efficacy of rocbrutinib in patients with relapsed\/refractory marginal zone lymphoma. Blood. 2024;144(Suppl 1):1635\u20136.","journal-title":"Blood"},{"issue":"16 Suppl","key":"2393_CR21","first-page":"TPS7100","volume":"44","author":"A Chen","year":"2026","unstructured":"Chen A, Woyach J, Seymour J, et al. ROCKET-CLL: a randomized, open-label, multicenter, phase 3 study of rocbrutinib (LP-168) versus pirtobrutinib in covalent BTK inhibitor (cBTKi) in pretreated relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) [abstract no. TPS7100]. J Clin Oncol. 2026;44(16 Suppl):TPS7100.","journal-title":"J Clin Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02393-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02393-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02393-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:12:05Z","timestamp":1794471125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02393-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":21,"alternative-id":["2393"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02393-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"28 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. Fung is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}